Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Rivaroxaban provides effective venous thromboembolic prophylaxis, but there are concerns about associated bleeding in total joint arthroplasty (TJA) patients. This study aimed to investigate whether the perioperative administration of tranexamic acid (TXA) in TJA patients receiving rivaroxaban for thromboprophylaxis is associated with a reduced risk of postoperative bleeding complications.
Methods: A healthcare database was utilized to identify all primary total knee arthroplasty (TKA) and total hip arthroplasty (THA) patients between 2015 and 2021. Patients receiving rivaroxaban during their in-hospital admission who also received TXA on the day of surgery were compared to those who did not receive TXA. Univariate and multivariable regression analyses assessed differences in 90-day bleeding, thromboembolic, and medical postoperative outcomes between cohorts. In total, 161,585 TJA patients were identified (TKA: 67.3%; THA: 32.7%), of which 41,899 (25.9%) received rivaroxaban alone, and 119,686 (74.1%) received rivaroxaban plus TXA.
Results: Multivariable analyses found that patients who received rivaroxaban and TXA had a reduced risk of aggregate bleeding complications (adjusted odds ratio [aOR] 0.7, 95% confidence interval [CI]: 0.7 to 0.7, P < 0.001), transfusion (aOR 0.4, 95% CI: 0.4 to 0.4, P < 0.001), acute anemia (aOR 0.7, 95% CI: 0.7 to 0.8, P < 0.001), deep vein thrombosis (aOR 0.8, 95% CI: 0.7 to 0.9, P < 0.001), and pulmonary embolism (aOR 0.8, 95% CI: 0.7 to 0.9, P = 0.012). No differences between cohorts were observed for the risk of stroke (aOR 0.9, 95% CI: 0.7 to 1.1, P = 0.31) and myocardial infarction (aOR 0.9, 95% CI: 0.7 to 1.1, P = 0.305). Procedure-specific subanalysis demonstrated a reduced risk of aggregate bleeding complications, transfusion, and acute anemia following THA and TKA.
Conclusions: Perioperative administration of TXA reduced the risk of bleeding complications without increasing thromboembolic risk among patients receiving rivaroxaban. Arthroplasty surgeons should consider administering TXA to primary THA and TKA patients receiving rivaroxaban.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.arth.2025.04.066 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Long-term oral glucocorticoid use is associated with complications, healthcare resource utilization, and costs among patients with dermatomyositis or polymyositis.
Clin Rheumatol
September 2025
Immunology Market Access, Johnson & Johnson, Horsham, PA, USA.
Introduction/objective: Oral glucocorticoids (OGC) are conventionally used as first-line treatment for dermatomyositis (DM) and polymyositis (PM). This study evaluated clinical and economic outcomes associated with long-term (LT) OGC use in DM/PM.
Methods: Adults with ≥ 2 medical claims of DM/PM 30‒365 days apart from January 1, 2016, to December 31, 2022, and ≥ 1 diagnosis code of a physician specialty of interest were selected from the MarketScan Commercial and Medicare Supplemental databases.
Geographic and Policy Factors Influence Telehealth Availability for Substance Use Disorder Treatment.
J Behav Health Serv Res
September 2025
Department of Health Policy and Management, Fay W. Boozman College of Public Health, University of Arkansas for Medical Sciences, 4301 W. Markham St., Little Rock, AR, USA.
Telehealth is increasingly a standard and routine clinical option, indicating a changing outlook for SUD treatment from in-person to the more convenient option of telehealth. As populations across geographies increasingly prefer telehealth, more research is warranted that focuses on how where a person lives is associated with telehealth availability. The authors used the Mental Health and Addiction Treatment Tracking Repository (MATTR 2024) to identify telehealth availability among all known licensed SUD treatment facilities in the USA (N = 10,492 facilities).
View Article and Find Full Text PDFVariations in Medical Clearance Testing for Mental Health Emergency Department Visits.
Pediatrics
September 2025
Division of Emergency Medicine, Boston Children's Hospital, Department of Pediatrics, Harvard Medical School, Boston, Massachusetts.
Background And Objectives: There are recommendations against routine medical clearance testing for children evaluated in the emergency department (ED) for mental health concerns. Our objective was to determine variation, factors, and costs associated with medical clearance testing during ED encounters for mental health concerns.
Methods: We conducted a cross-sectional study of ED encounters among children aged 5 to 18 years who presented to 35 US children's hospitals for mental health concerns (2016-2023).
Prediction of severe aneurysmal subarachnoid hemorrhage before rupture: Insights from a retrospective study.
Clin Neurol Neurosurg
September 2025
Department of Neurosurgery and Spine Surgery, University Hospital Essen, University of Duisburg-Essen, Essen, Germany; Center for Translational Neuro, & Behavioral Sciences (C-TNBS), University of Duisburg Essen, Germany.
Objective: Accurate prediction of the initial severity of aneurysmal subarachnoid hemorrhage (aSAH) is important for effective management of unruptured intracranial aneurysms (IA). This study aims to investigate patient and IA characteristics as pre-rupture predictors of severe aSAH.
Methods: This retrospective analysis included all patients aged 18 years or older diagnosed with acute aSAH at our center between January 2003 and June 2016.
Outcomes of resuscitative endovascular balloon occlusion of the aorta (REBOA) in severely injured adult trauma patients with isolated thoracic or abdominal trauma in Hemorrhagic shock.
Am J Emerg Med
September 2025
Department of Surgical Education, Orlando Regional Medical Center, Orlando, FL, USA; Department of Surgery, Division of Trauma and Surgical Critical Care, Orlando Regional Medical Center, Orlando, FL, USA. Electronic address:
Background: There is conflicting literature regarding mortality outcomes associated with REBOA usage in patients with severe thoracic or abdominal trauma. Our study aims to assess the benefits and negative implications of REBOA use in adult trauma patients in hemorrhagic shock with severe thoracic or abdominal injuries.
Methods: This retrospective cohort analysis utilized the American College of Surgeons Trauma Quality Improvement Program Participant Use File (ACS-TQIP-PUF) database from 2017 to 2023 to evaluate adult patients with severe isolated thoracic or abdominal trauma undergoing REBOA placement.